Company news
Recce Pharmaceuticals Ltd. news in 2021
Recce Pharmaceuticals Ltd.'s news releases, calls and decks from 2021, newest first.
Patients to be Dosed in Ph 1 IV Clinical Trial of R327
December 14, 2021
Update on Phase I/II Clinical Trial for Burn Wound Infection
December 6, 2021
Appendix 4C and Activity Report
October 29, 2021
Ethics Approval to Start Phase 1 Intravenous Clinical Trial
October 24, 2021
Reinstatement to Official Quotation
October 12, 2021
Court Orders Granted
October 11, 2021
Suspension from Official Quotation
October 11, 2021
Trading halt
October 8, 2021
R327 Phase I Clinical Trial Registered on ANZCTR
September 30, 2021
Recce Receives Further Innovation Connections Grant
August 11, 2021
Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
July 22, 2021
Anti-Viral Patent Granted in China
July 20, 2021
Outstanding Efficacy Against Flesh-Eating Bacteria
July 19, 2021
Multiple Patients Dosed in Topical Phase I/II Clinical Trial
July 11, 2021
Recce Clinical Pipeline Update
June 7, 2021
R327 Demonstrates World First Multiple Mechanisms of Action
May 27, 2021
R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
May 19, 2021
Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
May 3, 2021
RECCE 327 Registered for Topical Burns Study in Humans
April 15, 2021
Positive Sinusitis Patient Update - Special Access Scheme
April 7, 2021
Positive Sinusitis Data Against Infection
March 31, 2021
Anti-Viral Patent Granted in EU for RECCE Anti-Infectives
March 30, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
March 7, 2021
Appendix 4D and Half Yearly Report
February 25, 2021
Recce Applies for Dual Listing on Frankfurt Stock Exchange
February 23, 2021
Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
February 15, 2021
Further Encouraging COVID Results at Doherty
February 11, 2021
R&D Incentive Rebate Received
February 3, 2021